⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VIVS News
VivoSim Labs, Inc. Common Stock
VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling
globenewswire.com
VIVS
Form 8-K
sec.gov
VIVS
VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods
globenewswire.com
VIVS
Form 8-K
sec.gov
VIVS
Crystalys Therapeutics Strengthens Board of Directors and Leadership Team as Dotinurad Advances Through Global Phase 3 Development
prnewswire.com
AMGN
ABBV
VIVS
ESPR
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
globenewswire.com
VIVS
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
globenewswire.com
VIVS
Form 8-K
sec.gov
VIVS
Form 8-K
sec.gov
VIVS
VivoSim Provides Financial and Listing Compliance Update
globenewswire.com
VIVS